Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Associating transcriptional modules with colon cancer survival through weighted gene co-expression network analysis.

Liu R, Zhang W, Liu ZQ, Zhou HH.

BMC Genomics. 2017 May 9;18(1):361. doi: 10.1186/s12864-017-3761-z.

2.

Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.

Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ.

Int J Mol Sci. 2017 Jan 19;18(1). pii: E197. doi: 10.3390/ijms18010197. Review.

3.

TRIM37 promotes epithelial‑mesenchymal transition in colorectal cancer.

Hu CE, Gan J.

Mol Med Rep. 2017 Mar;15(3):1057-1062. doi: 10.3892/mmr.2017.6125. Epub 2017 Jan 16.

4.

Understanding molecular markers in recurrent oral squamous cell carcinoma treated with chemoradiation.

Gupta S, Kushwaha VS, Verma S, Khan H, Bhatt ML, Husain N, Negi MP, Bhosale VV, Ghatak A.

Heliyon. 2016 Dec 5;2(12):e00206. eCollection 2016 Dec.

5.

Expression and clinicopathological significance of the lncRNA HOXA11-AS in colorectal cancer.

Li T, Xu C, Cai B, Zhang M, Gao F, Gan J.

Oncol Lett. 2016 Nov;12(5):4155-4160. Epub 2016 Sep 14.

6.

A comprehensive meta-analysis of genetic associations between five key SNPs and colorectal cancer risk.

Hong Y, Wu G, Li W, Liu D, He K.

Oncotarget. 2016 Nov 8;7(45):73945-73959. doi: 10.18632/oncotarget.12154.

7.

Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples.

Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X.

Sci Rep. 2016 Sep 14;6:33273. doi: 10.1038/srep33273.

8.

A 19-Gene expression signature as a predictor of survival in colorectal cancer.

Abdul Aziz NA, Mokhtar NM, Harun R, Mollah MM, Mohamed Rose I, Sagap I, Mohd Tamil A, Wan Ngah WZ, Jamal R.

BMC Med Genomics. 2016 Sep 8;9(1):58. doi: 10.1186/s12920-016-0218-1.

9.

New trends in molecular and cellular biomarker discovery for colorectal cancer.

Aghagolzadeh P, Radpour R.

World J Gastroenterol. 2016 Jul 7;22(25):5678-93. doi: 10.3748/wjg.v22.i25.5678. Review.

10.

Comparison of Nanostring nCounter® Data on FFPE Colon Cancer Samples and Affymetrix Microarray Data on Matched Frozen Tissues.

Chen X, Deane NG, Lewis KB, Li J, Zhu J, Washington MK, Beauchamp RD.

PLoS One. 2016 May 13;11(5):e0153784. doi: 10.1371/journal.pone.0153784. eCollection 2016.

11.

High blood sugar levels significantly impact the prognosis of colorectal cancer patients through down-regulation of microRNA-16 by targeting Myb and VEGFR2.

Yang IP, Tsai HL, Huang CW, Lu CY, Miao ZF, Chang SF, Juo SH, Wang JY.

Oncotarget. 2016 Apr 5;7(14):18837-50. doi: 10.18632/oncotarget.7719.

12.

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgó E, Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van de Rijn M, Clarke MF.

N Engl J Med. 2016 Jan 21;374(3):211-22. doi: 10.1056/NEJMoa1506597.

13.

Overexpression of the S100A2 protein as a prognostic marker for patients with stage II and III colorectal cancer.

Masuda T, Ishikawa T, Mogushi K, Okazaki S, Ishiguro M, Iida S, Mizushima H, Tanaka H, Uetake H, Sugihara K.

Int J Oncol. 2016 Mar;48(3):975-82. doi: 10.3892/ijo.2016.3329. Epub 2016 Jan 11.

14.

Identifying molecular subtypes in human colon cancer using gene expression and DNA methylation microarray data.

Ren Z, Wang W, Li J.

Int J Oncol. 2016 Feb;48(2):690-702. doi: 10.3892/ijo.2015.3263. Epub 2015 Nov 24.

15.

Prognostic significance of Traf2- and Nck- interacting kinase (TNIK) in colorectal cancer.

Takahashi H, Ishikawa T, Ishiguro M, Okazaki S, Mogushi K, Kobayashi H, Iida S, Mizushima H, Tanaka H, Uetake H, Sugihara K.

BMC Cancer. 2015 Oct 24;15:794. doi: 10.1186/s12885-015-1783-y.

16.

Gene-expression analysis of a colorectal cancer-specific discriminatory transcript set on formalin-fixed, paraffin-embedded (FFPE) tissue samples.

Kalmár A, Wichmann B, Galamb O, Spisák S, Tóth K, Leiszter K, Nielsen BS, Barták BK, Tulassay Z, Molnár B.

Diagn Pathol. 2015 Jul 25;10:126. doi: 10.1186/s13000-015-0363-4.

17.

Colorectal Cancer Biomarkers: Where Are We Now?

Gonzalez-Pons M, Cruz-Correa M.

Biomed Res Int. 2015;2015:149014. doi: 10.1155/2015/149014. Epub 2015 May 27. Review.

18.

Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas.

Wong P, Hui A, Su J, Yue S, Haibe-Kains B, Gokgoz N, Xu W, Bruce J, Williams J, Catton C, Wunder JS, Andrulis IL, Gladdy R, Dickson B, O'Sullivan B, Liu FF.

Oncotarget. 2015 Nov 17;6(36):39127-39. doi: 10.18632/oncotarget.3926.

19.

The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers.

Ong CW, Chong PY, McArt DG, Chan JY, Tan HT, Kumar AP, Chung MC, Clément MV, Soong R, Van Schaeybroeck S, Waugh DJ, Johnston PG, Dunne PD, Salto-Tellez M.

Oncotarget. 2015 May 20;6(14):12763-73.

20.

IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers.

Fu T, Pappou EP, Guzzetta AA, Calmon Mde F, Sun L, Herrera A, Li F, Wolfgang CL, Baylin SB, Iacobuzio-Donahue CA, Tong W, Ahuja N.

Ann Surg. 2016 Feb;263(2):337-44. doi: 10.1097/SLA.0000000000001204.

Supplemental Content

Support Center